39541-22-5

Usage

Uses

Used in Pharmaceutical Industry:
2-(AcetylaMino)-2-deoxy-β-D-galactopyranosylaMine 3,4,6-Triacetate is used as a key intermediate in the synthesis of 1-N-(L-aspart-4-oyl)glycosylamines and their analogs. These synthesized compounds have potential applications in the development of new drugs, particularly those targeting specific biological receptors or enzymes.
Used in Chemical Research:
As a unique sugar derivative, 2-(AcetylaMino)-2-deoxy-β-D-galactopyranosylaMine 3,4,6-Triacetate is used as a research compound for understanding the structure-activity relationships of various biologically active molecules. Its synthesis and modification can lead to the discovery of new bioactive compounds with potential applications in medicine and other fields.
Used in Material Science:
2-(AcetylaMino)-2-deoxy-β-D-galactopyranosylaMine 3,4,6-Triacetate's unique chemical structure and properties may also find applications in material science, where it could be used to develop new materials with specific properties, such as improved biocompatibility or enhanced interaction with biological systems.

Upstream product

• 76375-60-5 (3R,4R,5R,6R)-3-acetamido-6-(acetoxymethyl)tetrahydro-2H-pyran-2,4,5-triyl triacetate 
• 14257-79-5 β-D-galactosamine hydrochloride 
• 39541-21-4 1-bromo-2-deoxy-2-acetamido-3,4,6-tri-O-acetyl-β-D-galactopyranoside 
• 1772-03-8 D-(+)-galactosamine hydrochloride 
• 39541-20-3 1-azido 2-deoxy-2-acetamido 3,4,6-tri-O-acetyl-β-D-galactopyranoside 
• 3006-60-8 2-acetamido-1,3,4,6-tetra-O-acetyl-2-deoxy-β-D-galactopyranose 
• 41355-44-6 2-acetamido-2,4,6,-tri-O-acetyl-1-chloro-1,2-dideoxy-α-D-galactopyranose 

Downstream Products

• 41676-46-4 5-oxo-4-[(tri-O-acetyl-2-acetylamino-β-D-2-deoxy-galactopyranosylcarbamoyl)-methyl]-oxazolidine-3-carboxylic acid benzyl ester 

Relevant academic research and scientific papers

Impact of Phosphorothioate Chirality on Double-Stranded siRNAs: A Systematic Evaluation of Stereopure siRNA Designs

Oligonucleotides are important therapeutic approaches, as evidenced by recent clinical successes with antisense oligonucleotides (ASOs) and double-stranded short interfering RNAs (siRNAs). Phosphorothioate (PS) modifications are a standard feature in the

Synthesis, Characterization, X-Ray Crystallography, and Antileishmanial Activities of N-Linked and O-Linked Glycopyranosides

Novel N-linked 5a-e and O-linked glycopyranosides 7a-e were synthesized in high yield from commercially available L-tartaric acid containing two asymmetric centers and C2 axis of symmetry. The compound L-tartaric acid was completely protected and then partially hydrolyzed to get the monoester, which upon treatment with different amino and hydroxyl derivatives of glycopyranoses gave the desired amides and esters. The synthesized derivatives were purified by chromatography and characterized by spectroanalytical techniques. The structure of compound 7c in the series was supported by X-ray analysis. Leishmanicidal activities of compounds 5a-e and 7a-e were investigated which showed moderate to good activities.

POLYNUCLEOTIDE CONSTRUCTS

Disclosed are polynucleotide constructs having a strand linked to a moiety carrying one or more auxiliary moieties. Also disclosed are polynucleotide constructs interrupted with a sugar analogue, and polynucleotide constructs with stereochemical^ enriched phosphorothioates. The polynucleotide constructs may be provided as hybridized polynucleotide constructs. Also featured are methods of delivery a polynucleotide construct to a cell and methods of reducing the expression of a protein in a cell by contacting the cell with the disclosed polynucleotide construct or hybridized polynucleotide construct.

POLYNUCLEOTIDE CONSTRUCTS HAVING AN AUXILIARY MOIETY NON-BIOREVERSIBLY LINKED TO AN INTERNUCLEOSIDE PHOSPHATE OR PHOSPHOROTHIOATE

The invention features a hybridized polynucleotide construct including a passenger strand, a guide strand loadable into a RISC complex, and one or more auxiliary moieties. At least one of the auxiliary moieties is non-bioreversibly linked to an internucleoside phosphate or phosphorothioate in the passenger strand. The invention further features methods of delivery a polynucleotide construct to a cell and methods of reducing the expression of a protein in a cell. The methods typically involve contacting the cell with the hybridized polynucleotide construct.

POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS

The invention features a hybridized polynucleotide construct containing a passenger strand, a guide strand loadable into a RISC complex, and (i) a 3'-terminal or an internucleotide non-bioreversible group in the guide strand; or (ii) a 5'-terminal, a 3'-terminal, or an internucleotide non-bioreversible group in the passenger strand, and a 5'-terminal, a 3'-terminal, or an internucleotide disulfide bioreversible group in the guide strand or the passenger strand. The invention also features methods of delivering a polynucleotide to a cell using the hybridized polynucleotide construct. The invention further features methods of reducing the expression of a polypeptide in a cell using the hybridized polynucleotide construct.

OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION

The present invention relates to ligand conjugates of oligonucleotides (e.g., iRNA agents) and methods for their preparation. The ligands are derived primarily from monosaccharides These conjugates are useful for the in vivo delivery of oligonucleotides.